| __timestamp | Dynavax Technologies Corporation | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 7751000 |
| Thursday, January 1, 2015 | 22180000 | 10251000 |
| Friday, January 1, 2016 | 37257000 | 9575000 |
| Sunday, January 1, 2017 | 27367000 | 10912000 |
| Monday, January 1, 2018 | 64770000 | 11049000 |
| Tuesday, January 1, 2019 | 74986000 | 11646000 |
| Wednesday, January 1, 2020 | 79256000 | 13265000 |
| Friday, January 1, 2021 | 100156000 | 25805000 |
| Saturday, January 1, 2022 | 131408000 | 35182000 |
| Sunday, January 1, 2023 | 152946000 | 94999000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Dynavax Technologies Corporation and Viridian Therapeutics, Inc. have shown contrasting approaches to SG&A optimization. From 2014 to 2023, Dynavax's SG&A expenses surged by over 760%, peaking at approximately $153 million in 2023. In contrast, Viridian's expenses grew by about 1,125%, reaching nearly $95 million in the same year. Despite Viridian's higher growth rate, Dynavax consistently spent more, indicating a potentially aggressive expansion strategy. This data highlights the importance of strategic cost management in sustaining growth and competitiveness in the biotech sector. As these companies continue to evolve, their ability to optimize SG&A costs will be pivotal in determining their long-term success.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Vericel Corporation and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Revenue Showdown: Dynavax Technologies Corporation vs Viridian Therapeutics, Inc.